Search Results
Sotorasib for KRAS G12C Mutated Advanced Non-Small Cell Lung Cancer
Sotorasib for KRAS G12C-Mutated Lung Cancer
Treating KRAS G12C Mutations
ASCO 2021 Lung Recap: CodeBreak 100: Sotorasib in KRAS G12C Mutation
Sotorasib: first targeted approval for KRAS G12C mutated NSCLC
Current treatment strategies KRASG12C–mutated NSCLC
Sotorasib shows as a tolerable treatment option for patients with KRASG12C-mutated advanced NSCLC
CodeBreaK 200: sotorasib versus docetaxel in pretreated KRAS G12C-mutant NSCLC
Sotorasib outperforms docetaxel in previously treated KRAS-mutated NSCLC | Melissa Johnson
Safety of sotorasib and panitumumab in advanced KRAS p.G12C-mutated colorectal cancer
ESMO highlights: KRAS G12C inhibitors
Sotorasib vs. Adagrasib as Treatment for KRAS G12C Mutated NSCLC - Case Based Panel Discussion
